Researchers continue to study how the drug may be combined with other therapies for positive patient outcomes
leading to a T300A conversion: GG, AG, AA) was determined at the Wellcome Trust Clinical Research Facility in Edinburgh as described previously for ATG16L (64) and Supplemental Methods for NOD2
More particularly: (i) steroidal anti-inflammatory substances of the corticosteroid type, in particular hydro cortisone, hydrocortisone derivatives such as hydrocortisone 17-butyrate, dexame thasone, dexamethasone phosphate, methylprednisolone or cortisone, (ii) non-steroidal anti-inflammatory substances, in particular oxicams such as piroxicam or tenoxicam, salicylates such as aspirin, disalcid, solprin or fendosal, acetic acid deriva tives such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin or clindanac, fenamates such as mefenamic, meclofenamic, flufenamic or niflumic, propionic acid derivatives such as ibuprofen, naproxen or benoxaprofen, pyrazoles such as phenyl butazone, oxyphenylbutazone, febrazone or azapropazone, (iii) natural or naturally occuring anti-inflammatory substances or substances that alleviate reddening and/or itching, in particular extracts or fractions from camomile, Aloe vera, Commiphora species, Rubia species, willow, willow-herb, oats, calendula, arnica, St John's wort, honeysuckle, rosemary, Passiflora incarnata, witch hazel, ginger or Echina cea, or single active compounds thereof, (iv) histamine receptor antagonists, serine protease inhibitors (e.g
Patients and Advocates: Please share your testimony in writing
